pelitinib
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 21, 2003 (NCT00067548)
Timeline
Indications
Mechanism of action
EGFR inhibitor
Irreversible inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C- Mol. weight
- 467.93 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL607707 ↗
Also known as
- ekb 569
- ekb-569
- ekb-569
- ekb-569
- ekb-569
- eki 569
- eki-569
- pelitinib
- pelitinib
- pelitinib
- pelitinib
- way-ekb-569
- way-ekb-569
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00098501 | Phase 1 | Oct 1, 2004 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00072748 | Phase 2 | Nov 10, 2003 | Pfizer, Wyeth |
| NCT00067548 | Phase 2 | Aug 21, 2003 | Pfizer, Wyeth |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 1 | 2003 |
| Wyeth | For profit | 2 | 0 | 1 | 2003 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2004 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2004 |
4 organizations
Page 1 / 1